期刊文献+

不同剂量尿激酶治疗急性心肌梗死的临床研究 被引量:1

Clinical study on different doses of urokinase in patients with acute myocardial infarction
暂未订购
导出
摘要 目的:探讨不同剂量尿激酶(UK)静脉滴注对急性心肌梗死(AMI)患者的疗效和出血并发症发生情况。方法:将96例AMI患者随机分为观察组(小剂量溶栓组)和对照组(大剂量溶栓组),各48例。观察组以UK60万U、对照组以UK150万U溶于5%葡萄糖溶液100ml中,30min内静滴完,其他基础治疗两组相同。结果:两组血管再通率、再梗死率、严重并发症发生率、死亡率比较均无显著性差异(P>0.05),但观察组出血发生率显著低于对照组(P<0.01)。结论:以小剂量UK60万U静滴治疗AMI安全、可靠。 Objective:To investigate the effects and adverse bleeding actions of different doses with intravenous urokinase in acute myocardial infarction(AMI).Methods:96 cases of AMI patients were randomly divided into two groups,48 cases in each group.The observation group was treated with intravenous urokinase 6×105 U in 100 ml of 5% glucose in 30 minutes and the control group with intravenous urokinase 1.5×106 U.Other treatment in patients of the two groups was correspondence.Results:The rate of reperfusion,reinfarction,severe complications and mortality had no statistical significance between the two groups(P0.05).But the bleeding rate of the observation group was lower than that of the control group(P0.01).Conclusion:AMI patients treated with intravenous urokinase 6×105 U is safe.
作者 王春伏
出处 《中国医药导报》 CAS 2010年第20期50-51,共2页 China Medical Herald
关键词 心肌梗死 尿激酶 溶栓治疗 副作用 Acute myocardial infarction Urokinase Thrombolytic therapy Side effect
  • 相关文献

参考文献6

二级参考文献25

  • 1刘旭,蒋毅萍,杨雪梅,游文纬,徐江平.护心灵对大鼠心肌缺血再灌注损伤的保护作用[J].中国药学杂志,2005,40(3):193-195. 被引量:6
  • 2杨建业,张迎春,王明江,唐俊明,汤敏,王家宁.大鼠左冠状动脉不同结扎时间对心肌梗死面积及心功能的影响[J].郧阳医学院学报,2006,25(2):74-77. 被引量:12
  • 3王屹立.急性心肌梗死的静脉溶栓治疗[J].中国医药导报,2007,4(04X):118-118. 被引量:10
  • 4Qureshi AI,Siddiqui AM,Suri MFK.Aggressive Mechanical Clot Disruption and Lowdose Intra-arterial Third-generation Thrombolttic Agent for ischemic Stroke:Apospective Study[J]. Neurosurgery,2002,51:1319-1329.
  • 5Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Nail Acad Sci USA, 2000, 97: 7458-7463.
  • 6Lutgens E, Cleutjens KBJM, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Nail Aced Sci. USA, 2000, 97: 7464-7469.
  • 7Kai H,Ikeda H, Yasukawa H, et al. Perpherial blood levels of matrix metalloproteinase-2 and 9 are evelated In patients with acute coronary sndrome. J Am Coll Cardiol , 1998,32:368-372.
  • 8Taku T, Toshio H, Hatsuyo K, et al. Cerivastatin, a HMG-CoA Reductase Inhibitor, Improves Endothelial Function In Elderly Diabetics winthin 3 days. Circulation, 2001,104:376-379.
  • 9Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med, 1999,340: 115-126.
  • 10Goran K Hansson. Immune Mechanism In Atherosclerosis Arteroscler Thromb Vasc Biol . 2001,21:1876-1890.

共引文献109

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部